JP2015529199A - パリペリドンハプテンに対する抗体及びその使用 - Google Patents

パリペリドンハプテンに対する抗体及びその使用 Download PDF

Info

Publication number
JP2015529199A
JP2015529199A JP2015528574A JP2015528574A JP2015529199A JP 2015529199 A JP2015529199 A JP 2015529199A JP 2015528574 A JP2015528574 A JP 2015528574A JP 2015528574 A JP2015528574 A JP 2015528574A JP 2015529199 A JP2015529199 A JP 2015529199A
Authority
JP
Japan
Prior art keywords
paliperidone
antibody
sample
labeled
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015528574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529199A5 (enExample
Inventor
リョホレンコ，エリック
サンカラン，バヌマティ
デコリー，トーマス，アール．
タブス，テレサ
コルト，リンダ
ヴリーゲン，マールテン
ハスペスラフ，ピーター，リック
Original Assignee
オルソ−クリニカル ダイアグノスティクス，インコーポレイティド
オルソ−クリニカル ダイアグノスティクス，インコーポレイティド
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オルソ−クリニカル ダイアグノスティクス，インコーポレイティド, オルソ−クリニカル ダイアグノスティクス，インコーポレイティド, ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical オルソ−クリニカル ダイアグノスティクス，インコーポレイティド
Publication of JP2015529199A publication Critical patent/JP2015529199A/ja
Publication of JP2015529199A5 publication Critical patent/JP2015529199A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2015528574A 2012-08-21 2013-08-20 パリペリドンハプテンに対する抗体及びその使用 Pending JP2015529199A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691634P 2012-08-21 2012-08-21
US61/691,634 2012-08-21
PCT/US2013/055733 WO2014031603A1 (en) 2012-08-21 2013-08-20 Antibodies to paliperidone haptens and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018027047A Division JP2018118972A (ja) 2012-08-21 2018-02-19 パリペリドンハプテンに対する抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2015529199A true JP2015529199A (ja) 2015-10-05
JP2015529199A5 JP2015529199A5 (enExample) 2018-04-12

Family

ID=50148304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015528574A Pending JP2015529199A (ja) 2012-08-21 2013-08-20 パリペリドンハプテンに対する抗体及びその使用
JP2018027047A Pending JP2018118972A (ja) 2012-08-21 2018-02-19 パリペリドンハプテンに対する抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018027047A Pending JP2018118972A (ja) 2012-08-21 2018-02-19 パリペリドンハプテンに対する抗体及びその使用

Country Status (8)

Country Link
US (4) US20140057297A1 (enExample)
EP (1) EP2888287A4 (enExample)
JP (2) JP2015529199A (enExample)
CN (1) CN104736566A (enExample)
AU (3) AU2013305938B2 (enExample)
CA (1) CA2882489A1 (enExample)
HK (1) HK1211956A1 (enExample)
WO (1) WO2014031603A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018118972A (ja) * 2012-08-21 2018-08-02 ヤンセン ファーマシューティカ エヌ．ベー． パリペリドンハプテンに対する抗体及びその使用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2888284T (pt) 2012-08-21 2022-11-18 Janssen Pharmaceutica Nv Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
CN104736564B (zh) 2012-08-21 2019-02-05 詹森药业有限公司 喹硫平半抗原的抗体及其用途
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
PT2888593T (pt) 2012-08-21 2018-12-12 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilizações dos mesmos
CA2882595C (en) 2012-08-21 2019-06-04 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine haptens and use thereof
PT3321254T (pt) 2012-08-21 2020-10-20 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
WO2017106501A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
JP6994461B2 (ja) 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンに対する抗体及びその使用
CN107137715B (zh) * 2017-04-26 2019-02-19 石家庄蒎格医药科技有限公司 一种帕利哌酮聚乙二醇缀合前药及制备
CN112730825B (zh) * 2020-12-17 2022-09-06 北京丹大生物技术有限公司 一种用于检测利培酮和/或9-羟基利培酮的检测试剂和检测试剂盒
CN112608310B (zh) * 2020-12-17 2022-03-29 北京丹大生物技术有限公司 一种利培酮和9-羟基利培酮半抗原、抗原和抗体以及其应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61130263A (ja) * 1984-11-27 1986-06-18 ヘキスト・セラニーズ・コーポレイション 二官能性ハプテンおよび免疫化学的ハプテン測定法
JPH02111798A (ja) * 1988-10-20 1990-04-24 Fuji Photo Film Co Ltd 蛋白質修飾物
JPH0627108A (ja) * 1991-06-07 1994-02-04 Eastman Kodak Co 新規標識薬物ハプテン類似体を用いるイムノアッセイ
JPH1151935A (ja) * 1997-08-06 1999-02-26 Aisin Seiki Co Ltd 複数種類のターゲット分子の同時検出方法
US20030099636A1 (en) * 2000-06-20 2003-05-29 Epshtein Oleg Iliich Curing method for pathologic syndrome and medicinal preparation
JP2004323522A (ja) * 2003-04-22 2004-11-18 F Hoffmann La Roche Ag エファビレンツを検出するための試薬
JP2007514157A (ja) * 2003-12-12 2007-05-31 インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング アッセイ
JP2007531724A (ja) * 2004-04-05 2007-11-08 クアーク・ファーマスーティカルス、インコーポレイテッド ５’−デオキシ−５’−メチルチオアデノシンに対する抗体及びその使用
JP2010507648A (ja) * 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド グルタミン酸ｎｍｄａ活性を有する新規向精神薬
JP2010512537A (ja) * 2006-12-11 2010-04-22 ジェンザイム・コーポレーション 間接側方流動サンドイッチアッセイ
JP2011102316A (ja) * 2003-10-23 2011-05-26 Otsuka Pharmaceut Co Ltd 放出制御性無菌注射アリピプラゾール製剤および方法
JP2011519048A (ja) * 2008-04-29 2011-06-30 サイケメディクス コーポレイション 固相多分析物アッセイ法
WO2011115733A1 (en) * 2010-03-16 2011-09-22 Saladax Biomedical Inc. Risperidone immunoassay

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
ES2153373T3 (es) 1992-05-29 2001-03-01 Lilly Co Eli Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central.
DE69323244T2 (de) 1992-06-26 1999-07-08 Johnson & Johnson Clinical Diagnostics, Inc., Rochester, N.Y. Immunotests unter Verwendung von markierten Thyronin-Analogen
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
AU694147B2 (en) 1993-11-19 1998-07-16 Alkermes, Inc. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
AU710106B2 (en) 1994-06-10 1999-09-16 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US6139800A (en) 1997-06-23 2000-10-31 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
DE60335428D1 (de) * 2002-01-31 2011-02-03 Randox Lab Ltd Immunogene, Antikörper und Konjugate für Ketamin und dessen Metaboliten
CN1646161A (zh) 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
JP2005533009A (ja) 2002-03-28 2005-11-04 イーライ・リリー・アンド・カンパニー ピペラジン置換されたアリールベンゾジアゼピン類およびそのドーパミン受容体アンタゴニストとしての精神病性障害の処置のための使用
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
CA2494109A1 (en) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
AU2003264915A1 (en) 2002-08-05 2004-02-25 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
US20040193446A1 (en) 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
NZ543960A (en) 2003-05-09 2008-11-28 Univ Duke CD20-specific antibodies and methods of employing same
CA2536073A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
PT1664007E (pt) 2003-09-23 2010-02-15 Fermion Oy Preparação de quetiapina
BRPI0415165A (pt) 2003-10-01 2007-01-09 Adolor Corp composto heterocìclico espirocìclico, composição farmacêutica, método para ligar receptores opióides, métodos para prevenir ou tratar dor, disfunção gastrointestinal, um distúrbio do trato urogenital, um distúrbio imunomodulatório, um distúrbio inflamatório, um distúrbio de função respiratória, ansiedade, distúrbio do humor, um distúrbio relacionado a estresse, distúrbio do sistema nervoso simpático, tosse, e um distúrbio motor, método para tratar uma lesão traumática ao sistema nervoso central, métodos para prevenir ou tratar acidente vascular, arritmia cardìaca, glaucoma, e disfunção sexual, métodos para tratar uma condição selecionada do grupo consistindo de choque, edema cerebral, isquemia cerebral, déficit cerebral após cirurgia cardìaca (bypass) e enxerto, lupus eritematoso sistêmico, doença de hodgkin, doença de sjogren, epilepsia, e rejeição em transplantes de órgão e enxertos de pele, e para tratar dependência de substáncias, métodos para melhorar a sobrevivência de órgãos e células, e cardioproteção após infarto do miocárdio, métodos para reduzir a necessidade de anestesia, para produzir ou manter um estado anestésico, derivado radiomarcado de um composto, derivado isotopicamente marcado de um composto, composto e método de diagnóstico por imagem
GB0328892D0 (en) * 2003-12-12 2004-01-14 Inverness Medical Switzerland Positive signal assay for analytes
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
WO2005103250A1 (ja) 2004-04-26 2005-11-03 Takami Matsuyama 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
US20080214808A1 (en) 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US20100061933A1 (en) 2006-10-20 2010-03-11 Naoki Kimura Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
AU2007332473B2 (en) 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
WO2008082979A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
US8071767B2 (en) 2007-01-08 2011-12-06 Actavis Group Ptc Ehf Process for preparation of 9-hydroxy-3-(2-chloroethyl)-2-methyl-4H-pyrido[1,2-A]pyrimidin-4-one hydrochloride
CN101245065B (zh) 2007-02-14 2010-05-19 江苏恩华药业股份有限公司 制备苯并异噁唑衍生物的方法及其中间体
AU2008303540B2 (en) 2007-09-27 2012-04-26 Novartis Ag Drug monitoring assay
US8133743B2 (en) 2007-10-19 2012-03-13 Roche Diagnostics Operations, Inc. Phenobarbital derivatives useful in immunoassay
JP5828762B2 (ja) 2008-07-21 2015-12-09 プロビオドルグ エージー 診断用抗体アッセイ
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
WO2010033270A1 (en) 2008-09-17 2010-03-25 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
EP2350077B1 (en) 2008-10-14 2016-01-27 Entasis Therapeutics Limited Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
EP2347015A4 (en) * 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv METHOD FOR THE TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GEN
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
AU2010206376B2 (en) * 2009-01-26 2012-10-18 Egalet Ltd. Controlled release formulations with continuous efficacy
JP2012520073A (ja) 2009-03-10 2012-09-06 ベイラー リサーチ インスティテュート 抗原提示細胞ターゲティングワクチン
AU2010266040B2 (en) 2009-06-25 2015-01-15 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
KR101770844B1 (ko) 2009-07-31 2017-08-23 아센디스 파마 에이에스 폴리에틸렌 글리콜 기반의 생분해성 수불용성 하이드로겔
CA2771436A1 (en) 2009-08-17 2011-02-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US8076097B2 (en) 2009-08-19 2011-12-13 Saladax Biomedical Inc. Imatinib immunoassay
EP2485767A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
EP2343296A1 (en) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. A process for the purification of paliperidone
EP2519101B1 (en) 2009-12-31 2015-08-19 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
SI2544536T1 (sl) 2010-03-11 2019-03-29 Kempharm, Inc. Maščobno kislinski konjugati kvetiapina proces za njih izdelavo in uporabo
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
WO2011159537A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2585066B1 (en) 2010-06-24 2018-09-26 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2012003418A2 (en) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
CN102276592B (zh) 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法、分析方法
CN102276624B (zh) 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法和高效液相色谱分析方法
US20140243254A1 (en) 2011-08-12 2014-08-28 Ascendis Pharma A/S Polymeric Hyperbranched Carrier-Linked Prodrugs
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2014028800A1 (en) 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
PT3321254T (pt) 2012-08-21 2020-10-20 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
PL2888263T3 (pl) * 2012-08-21 2018-10-31 Janssen Pharmaceutica Nv Hapteny rysperydonu i paliperydonu
CN104736564B (zh) 2012-08-21 2019-02-05 詹森药业有限公司 喹硫平半抗原的抗体及其用途
EP2888277A4 (en) * 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
PT2888593T (pt) 2012-08-21 2018-12-12 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilizações dos mesmos
WO2014031662A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine and use thereof
ES2701062T3 (es) 2012-08-21 2019-02-20 Janssen Pharmaceutica Nv Haptenos de olanzapina
CA2882595C (en) 2012-08-21 2019-06-04 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine haptens and use thereof
PL2888257T3 (pl) 2012-08-21 2018-02-28 Janssen Pharmaceutica Nv Hapteny kwetiapiny do zastosowania w testach immunologicznych
PT2888284T (pt) 2012-08-21 2022-11-18 Janssen Pharmaceutica Nv Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
CA2882489A1 (en) * 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
PL2888258T3 (pl) * 2012-08-21 2019-10-31 Janssen Pharmaceutica Nv Hapteny paliperydonu
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017106501A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61130263A (ja) * 1984-11-27 1986-06-18 ヘキスト・セラニーズ・コーポレイション 二官能性ハプテンおよび免疫化学的ハプテン測定法
JPH02111798A (ja) * 1988-10-20 1990-04-24 Fuji Photo Film Co Ltd 蛋白質修飾物
JPH0627108A (ja) * 1991-06-07 1994-02-04 Eastman Kodak Co 新規標識薬物ハプテン類似体を用いるイムノアッセイ
JPH1151935A (ja) * 1997-08-06 1999-02-26 Aisin Seiki Co Ltd 複数種類のターゲット分子の同時検出方法
US20030099636A1 (en) * 2000-06-20 2003-05-29 Epshtein Oleg Iliich Curing method for pathologic syndrome and medicinal preparation
JP2004323522A (ja) * 2003-04-22 2004-11-18 F Hoffmann La Roche Ag エファビレンツを検出するための試薬
JP2011102316A (ja) * 2003-10-23 2011-05-26 Otsuka Pharmaceut Co Ltd 放出制御性無菌注射アリピプラゾール製剤および方法
JP2007514157A (ja) * 2003-12-12 2007-05-31 インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング アッセイ
JP2007531724A (ja) * 2004-04-05 2007-11-08 クアーク・ファーマスーティカルス、インコーポレイテッド ５’−デオキシ−５’−メチルチオアデノシンに対する抗体及びその使用
JP2010507648A (ja) * 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド グルタミン酸ｎｍｄａ活性を有する新規向精神薬
JP2010512537A (ja) * 2006-12-11 2010-04-22 ジェンザイム・コーポレーション 間接側方流動サンドイッチアッセイ
JP2011519048A (ja) * 2008-04-29 2011-06-30 サイケメディクス コーポレイション 固相多分析物アッセイ法
WO2011115733A1 (en) * 2010-03-16 2011-09-22 Saladax Biomedical Inc. Risperidone immunoassay

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANN. 1ST. SUPER. SANITA (1991) VOL.27, NO.1, PP.149-154, インターネット＜URL: HTTP://ALLEANZACONTROI, JPN7016003506, ISSN: 0003443098 *
CLIN. PHARMACOL. THER. (1993), VOL.54, PP.257-268, JPN6016044545, ISSN: 0003443097 *
DU HONGWU: "PREPARATION OF STEROID ANTIBODIES AND PARALLEL DETECTION 以下備考", ANALYTICAL CHEMISTRY, vol. V76 N20, JPN5011003653, 15 October 2004 (2004-10-15), pages 6166 - 6171, ISSN: 0003659782 *
HONGWU DU: "PARALLEL DETECTION AND QUANTIFICATION USING NINE IMMUNOASSAYS IN A PROTEIN MICROARRAY FOR DRUG FROM", BIOMEDICAL MICRODEVICES, vol. V7 N2, JPN5011003652, 1 June 2005 (2005-06-01), pages 143 - 146, ISSN: 0003659783 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018118972A (ja) * 2012-08-21 2018-08-02 ヤンセン ファーマシューティカ エヌ．ベー． パリペリドンハプテンに対する抗体及びその使用

Also Published As

Publication number Publication date
JP2018118972A (ja) 2018-08-02
US20190338047A1 (en) 2019-11-07
WO2014031603A1 (en) 2014-02-27
CA2882489A1 (en) 2014-02-27
US20170129968A1 (en) 2017-05-11
US11225527B2 (en) 2022-01-18
EP2888287A1 (en) 2015-07-01
AU2019284029B2 (en) 2022-03-10
EP2888287A4 (en) 2016-04-20
HK1211956A1 (en) 2016-06-03
AU2013305938A1 (en) 2015-03-05
US20140057297A1 (en) 2014-02-27
AU2013305938B2 (en) 2017-08-17
US20170298147A1 (en) 2017-10-19
AU2017261585A1 (en) 2017-12-07
AU2019284029A1 (en) 2020-01-23
US10370457B2 (en) 2019-08-06
AU2017261585B2 (en) 2019-09-26
CN104736566A (zh) 2015-06-24

Similar Documents

Publication Publication Date Title
JP6971927B2 (ja) リスペリドンハプテンへの抗体及びその使用
JP6726715B2 (ja) アリピプラゾールハプテンに対する抗体及びその使用
JP6637580B2 (ja) クエチアピンハプテンに対する抗体及びその使用
JP6389177B2 (ja) オランザピンハプテンに対する抗体及びその使用
US11225527B2 (en) Antibodies to paliperidone haptens and use thereof
JP6286429B2 (ja) パリペリドンのハプテン
JP6131500B2 (ja) リスペリドン及びパリペリドンのハプテン
HK40018877A (en) Antibodies to olanzapine haptens and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170222

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171017

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180219

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180403

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180608